Wenjun Zheng

Dr. Wenjun Zheng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Heliyon
Verified
Journal Article
Open access
XLXianghui Li
Xianghui Li
YCYuanyuan Chen
Yuanyuan Chen
YDYuxiang Dong
Yuxiang Dong
ZMZhongjin Ma
Zhongjin Ma
WZWenjun Zheng
Wenjun Zheng
YLYoukun Lin
Youkun Lin
The immune microenvironment influenced clinical outcomes and treatment response of gastric cancer (GC) patients. Though thousands of immune-related genes (IRGs) have been identified, their effects on GC are not fully understood. The objective of the study is to analyze the correlations between the expression and effect of IRGs and clinical outcomes. Moreover, we evaluate the efficacy and value of utilizing the immune-related genes signature as a prognosis prediction model for GC patients. We identified the differentially expressed IRGs and systematically analyzed their functions. We constructed a novel GC prognostic signature and a new nomogram, Moreover, we explored the infiltrated immune cell types in the immune microenvironment and discussed the genetic variation in GC IRGs. Eight IRGs, including CCL15, MSR1, GNAI1, NR3C1, ITGAV, NMB, AEN, and TGFBR1 were identified. Based on the prognostic signature, GC patients were distinguished into two subtype groups. As verified in multiple datasets, the prognostic signature exhibited good performance in predicting the prognosis (AUC = 0.803, P-value <0.001) and revealed the different clinical features and infiltrated immune cell types in the immune microenvironment. In summary, we found that IRGs contributed to GC prognosis prediction and constructed an IRGs-based GC prognostic signature, which could serve as an effective prognostic stratification tool.

1 September 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
HTHongyu Tao
Hongyu Tao
WZWenjun Zheng
Wenjun Zheng
Background: Non-tuberculous mycobacteria (NTM) skin and soft tissue infections (SSTIs) are increasingly recognized but underdiagnosed in China. Methods: This retrospective study analyzed 15 confirmed cases of NTM SSTIs treated at a southern Chinese hospital from 2012 to 2022. Clinical data, including demographics, clinical presentations, comorbidities, diagnostic methods, treatment regimens, and outcomes, were collected and analyzed. Diagnostic efficacy of conventional culture and metagenomic next-generation sequencing (mNGS) was compared. Results: The median age of patients was 57 years, and 66.7% were farmers. Pathogens identified included Mycobacterium abscessus (20.0%), M. marinum (13.3%), and rapidly growing mycobacteria (13.3%). Immunocompromised states, such as anti-interferon-gamma autoantibody positivity, were present in 40.0%. mNGS demonstrated superior diagnostic performance, achieving a detection rate of 86.7% (13/15 cases), compared to 26.7% for culture. Treatment regimens, including clarithromycin, rifampin, ethambutol, and moxifloxacin, lasted 1– 24 months. Outcomes showed cure in 8 patients (53.3%), improvement in 6 (40.0%), and 1 lost to follow-up. Conclusion: NTM SSTIs present significant diagnostic and therapeutic challenges, with clinical variability and frequent association with immunocompromised states. M. abscessus, M. marinum, and M. avium were the predominant pathogens. mNGS improves detection but still should complement culture. Precise pathogen identification and tailored therapy are essential for achieving optimal outcomes, and further studies are needed to refine diagnostics and treatment strategies.

3 September 2025 in Frontiers in Allergy
Verified
Journal Article
Open access
PDF file
WXWanyan Xiang
Wanyan Xiang
CLChengxiang Lian
Chengxiang Lian
JLJiarong Lu
Jiarong Lu
WZWenjun Zheng
Wenjun Zheng
QLQiuju Li
Qiuju Li
Background: Netherton syndrome (NS) is a rare, autosomal recessive disease resulting from a mutation in the pathogenic variants in the Kazal type 5 (SPINK5) gene. In recent years, the targeted treatment of biological agents has increasingly emerged as a focal point of research.Case reports: We reported a 4-month-old child and 19-year-old female, both presenting with symptoms including erythema, scaling, and recurring episodes. Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS. The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab. Both patients had swift and enduring enhancement of skin lesions during the follow-up period.Conclusion: NS is an uncommon and frequently misdiagnosed hereditary dermatological disease. The management strategies for this condition are diverse, and no consensus exists. We implemented various biologic regimens for distinct patients, all demonstrating favorable outcomes and satisfactory tolerance. Besides, monitoring and evaluating the long-term safety of biologics in combination is essential.

9 November 2024 in Medcomm
Verified
Journal Article
Open access
XLXianghui Li
Xianghui Li
HWHaoran Wang
Haoran Wang
ZLZhiyan Li
Zhiyan Li
SLSong Liu
Song Liu
YCYuanyuan Chen
Yuanyuan Chen
WGWenxian GUAN
Wenxian GUAN
The precise and effective activation of the immune response is crucial in promising therapy curing cancer. Photoimmunotherapy (PIT) is an emerging strategy for precise regulation and highly spatiotemporal selectivity. However, this approach faces a significant challenge due to the off‐target effect and the immunosuppressive microenvironment. To address this challenge, a nanoscale full‐active pharmaceutical ingredient (API) photo‐immune stimulator was developed. This formulation overcomes the limitations of PIT by strengthening the ability to penetrate tumors deeply and inducing precise and potent mitochondria‐targeted dual‐mode photodynamic therapy and photothermal therapy. Along with inhibiting overexpressed Hsp90, this nanosensitizer in turn improves the immunosuppressive microenvironment. Ultimately, this mitochondria‐targeted PIT demonstrated potent antitumor efficacy, achieving a remarkable inhibition rate of ≥95% for both established primary tumors and distant abscopal tumors. In conclusion, this novel self‐delivery full‐API nanosystem enhances the efficacy of phototherapy and reprograms the immunosuppressive microenvironment, thereby holding great promise in the development of precise and effective immunotherapy.

1 May 2026 in Immunologic Research
Verified
Journal Article
Closed access
QWQiu-Ju Wei
Qiu-Ju Wei
JLJia-Rong Lu
Jia-Rong Lu
WXWan-Yan Xiang
Wan-Yan Xiang
HLHai-Qi Liang
Hai-Qi Liang
SZSi-Qi Zhang
Si-Qi Zhang
WZWenjun Zheng
Wenjun Zheng

14 June 2025 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
YCYuanyuan Chen
Yuanyuan Chen
ZYZhijian Yao
Zhijian Yao
ZRZhuren Ruan
Zhuren Ruan
GWGao Wei
Gao Wei
WZWenjun Zheng
Wenjun Zheng
XLXianghui Li
Xianghui Li
The skin microbiota is crucial in defending against toxic, solar, and pathogenic assaults, yet it can also precipitate dermatosis when its equilibrium is disrupted. The composition and distribution of various microorganisms within the skin maintain a dynamic balance, modulating the barrier function and the immune system, thereby constituting the skin microbiota. This microbiota not only offers new insights into pathological microbe-host interactions and associated dermatoses but also inspires innovative therapeutic strategies that promise high efficacy and reduced symptomatology. In this review, we synthesize recent advancements in the field of skin microbiota, focusing on its relationship with dermatosis and the application of microbiota-based therapies in skin diseases. Our aim is to scrutinize the current understanding of the skin microbiota’s role, ranging from a protective barrier to a causative agent of dermatosis.